[{"id":"ef460ada-1956-4c98-ae47-6b4d433dca90","acronym":"ReFocus","url":"https://clinicaltrials.gov/study/NCT04526106","created_at":"2021-01-18T21:40:34.651Z","updated_at":"2025-02-25T17:30:23.437Z","phase":"Phase 1/2","brief_title":"REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors","source_id_and_acronym":"NCT04526106 - ReFocus","lead_sponsor":"Elevar Therapeutics","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lirafugratinib (RLY-4008)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/27/2024","primary_completion_date":" 09/27/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-01-30"},{"id":"f1eb15be-99b0-4993-89d8-1f3e74e59506","acronym":"","url":"https://clinicaltrials.gov/study/NCT05297903","created_at":"2022-03-28T13:52:59.235Z","updated_at":"2024-07-02T16:35:05.357Z","phase":"Phase 2","brief_title":"XmAb20717 in Advanced Biliary Tract Cancers","source_id_and_acronym":"NCT05297903","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" FGFR2 • IDH1 • NTRK","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion","tags":["FGFR2 • IDH1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-07"},{"id":"e391f2a5-896d-4821-b066-fdd97cba862d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04919642","created_at":"2021-06-10T01:52:34.634Z","updated_at":"2024-07-02T16:35:07.347Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma","source_id_and_acronym":"NCT04919642","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinengotinib (TT-00420)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-04-26"},{"id":"87f0861a-71c2-4555-9071-1764face39ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04641871","created_at":"2021-08-24T14:53:56.048Z","updated_at":"2024-07-02T16:35:07.851Z","phase":"Phase 1","brief_title":"Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies","source_id_and_acronym":"NCT04641871","lead_sponsor":"Symphogen A/S","biomarkers":" FGFR2 • IDH1","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion","tags":["FGFR2 • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • S95018 • Sym021 • Sym022"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/12/2020","start_date":" 10/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-24"},{"id":"1f885c20-bddc-441e-b3b3-ce916b0c4eaf","acronym":"FIGHT-209","url":"https://clinicaltrials.gov/study/NCT05267106","created_at":"2022-03-04T15:53:30.724Z","updated_at":"2024-07-02T16:35:22.897Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations","source_id_and_acronym":"NCT05267106 - FIGHT-209","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-01-19"},{"id":"2354d741-07d7-4fa3-9724-54f92f01122f","acronym":"FORTUNE","url":"https://clinicaltrials.gov/study/NCT04962867","created_at":"2021-07-15T13:06:08.522Z","updated_at":"2025-02-25T13:35:52.987Z","phase":"Phase 2","brief_title":"NCCH2006/MK010 Trial (FORTUNE Trial)","source_id_and_acronym":"NCT04962867 - FORTUNE","lead_sponsor":"National Cancer Center, Japan","biomarkers":" EGFR • KRAS • BRAF • ALK • NRAS • FGFR2 • ROS1 • FGFR4 • NTRK","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR2 mutation • FGFR2 fusion • FGFR mutation","tags":["EGFR • KRAS • BRAF • ALK • NRAS • FGFR2 • ROS1 • FGFR4 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR2 mutation • FGFR2 fusion • FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tasfygo (tasurgratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-08"},{"id":"b7659aa4-c8c0-4419-bda6-e8c9eced4212","acronym":"PERIO-02","url":"https://clinicaltrials.gov/study/NCT05220722","created_at":"2023-07-27T22:08:59.303Z","updated_at":"2025-02-25T16:32:45.067Z","phase":"Phase 1/2","brief_title":"Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors","source_id_and_acronym":"NCT05220722 - PERIO-02","lead_sponsor":"TriSalus Life Sciences, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • nelitolimod (SD-101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 03/02/2022","start_date":" 03/02/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-12-25"},{"id":"45f9e4a5-fb7c-4d84-a994-fb30e1410536","acronym":"FIDES-01","url":"https://clinicaltrials.gov/study/NCT03230318","created_at":"2021-01-17T17:21:24.827Z","updated_at":"2025-02-25T13:34:55.963Z","phase":"Phase 2","brief_title":"Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT03230318 - FIDES-01","lead_sponsor":"Basilea Pharmaceutica","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e derazantinib (ARQ 087)"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 09/28/2017","start_date":" 09/28/2017","primary_txt":" Primary completion: 10/25/2022","primary_completion_date":" 10/25/2022","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2023-12-19"},{"id":"9348086e-e891-40b0-a92b-8bc10d06743b","acronym":"FIDES-02","url":"https://clinicaltrials.gov/study/NCT04045613","created_at":"2021-01-17T17:51:34.154Z","updated_at":"2025-02-25T13:35:26.193Z","phase":"Phase 1b/2","brief_title":"Derazantinib and Atezolizumab in Patients With Urothelial Cancer","source_id_and_acronym":"NCT04045613 - FIDES-02","lead_sponsor":"Basilea Pharmaceutica","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR3 mutation","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • derazantinib (ARQ 087)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 08/02/2019","start_date":" 08/02/2019","primary_txt":" Primary completion: 10/04/2022","primary_completion_date":" 10/04/2022","study_txt":" Completion: 10/04/2022","study_completion_date":" 10/04/2022","last_update_posted":"2023-10-13"},{"id":"2b64af10-d65b-4d9e-b123-5cd01fb9300a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627063","created_at":"2022-11-25T15:58:10.134Z","updated_at":"2024-07-02T16:35:38.335Z","phase":"Phase 1","brief_title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05627063","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABSK121"],"overall_status":"Recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-09-01"},{"id":"2fd38c52-b64b-4e26-aac4-6e079d9c3e0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05991947","created_at":"2023-08-15T19:10:06.072Z","updated_at":"2024-07-02T16:35:39.996Z","phase":"","brief_title":"Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer","source_id_and_acronym":"NCT05991947","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-15"},{"id":"934d3478-921a-4635-9f03-493d15ba270a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05244551","created_at":"2022-02-17T18:22:17.151Z","updated_at":"2024-07-02T16:36:00.316Z","phase":"Phase 1","brief_title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05244551","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lavengratinib (ABSK061)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2022-11-16"},{"id":"de090239-ac97-4a09-a8c1-e09e9af7bef0","acronym":"LUDOC II","url":"https://clinicaltrials.gov/study/NCT02518256","created_at":"2021-01-18T12:10:09.769Z","updated_at":"2024-07-02T16:36:04.422Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity","source_id_and_acronym":"NCT02518256 - LUDOC II","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 270","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-06"},{"id":"aec26925-41ed-4f2f-9267-a32e6531e375","acronym":"","url":"https://clinicaltrials.gov/study/NCT02450136","created_at":"2022-06-02T19:55:13.662Z","updated_at":"2024-07-02T16:36:08.673Z","phase":"","brief_title":"Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors","source_id_and_acronym":"NCT02450136","lead_sponsor":"Samsung Medical Center","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 amplification","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 10/08/2015","start_date":" 10/08/2015","primary_txt":" Primary completion: 07/30/2017","primary_completion_date":" 07/30/2017","study_txt":" Completion: 02/01/2018","study_completion_date":" 02/01/2018","last_update_posted":"2022-06-15"},{"id":"c7ffedfa-b221-47a0-8188-045db5ae4afc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02691793","created_at":"2021-01-18T13:07:48.373Z","updated_at":"2024-07-02T16:36:08.891Z","phase":"Phase 4","brief_title":"Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors","source_id_and_acronym":"NCT02691793","lead_sponsor":"Samsung Medical Center","biomarkers":" RET • FGFR2","pipe":" | ","alterations":" RET fusion • FGFR2 mutation • FGFR2 fusion • FGFR mutation • RET positive","tags":["RET • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • FGFR2 mutation • FGFR2 fusion • FGFR mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 11/20/2017","start_date":" 11/20/2017","primary_txt":" Primary completion: 08/30/2019","primary_completion_date":" 08/30/2019","study_txt":" Completion: 11/19/2019","study_completion_date":" 11/19/2019","last_update_posted":"2022-06-15"},{"id":"d4d894ac-2658-4499-8ad7-5be03852e67a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173142","created_at":"2021-12-29T13:53:45.797Z","updated_at":"2025-02-25T14:52:10.343Z","phase":"Phase 1/2","brief_title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","source_id_and_acronym":"NCT05173142","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":" | ","alterations":" PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 01/22/2022","start_date":" 01/22/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-03-08"},{"id":"f45473e2-7a95-4d17-95ba-c86a27ceffbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01244438","created_at":"2021-01-18T05:00:42.606Z","updated_at":"2024-07-02T16:36:19.600Z","phase":"Phase 2","brief_title":"Study of FP-1039 in Subjects With Endometrial Cancers","source_id_and_acronym":"NCT01244438","lead_sponsor":"Five Prime Therapeutics, Inc.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 mutation • FGFR mutation • FGFR2 S252W","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR mutation • FGFR2 S252W"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FP-1039"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2021-12-13"},{"id":"545f4b46-aa6a-4f4c-9242-8f406a200a71","acronym":"","url":"https://clinicaltrials.gov/study/NCT05086666","created_at":"2021-10-21T13:53:10.418Z","updated_at":"2024-07-02T16:36:22.688Z","phase":"Phase 1b/2","brief_title":"A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547","source_id_and_acronym":"NCT05086666","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fexagratinib (ABSK091)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 06/03/2021","start_date":" 06/03/2021","primary_txt":" Primary completion: 08/14/2023","primary_completion_date":" 08/14/2023","study_txt":" Completion: 05/27/2024","study_completion_date":" 05/27/2024","last_update_posted":"2021-10-21"},{"id":"8e96cc7a-6dec-4aa5-96fd-2012bb5fe9bb","acronym":"LUDOC","url":"https://clinicaltrials.gov/study/NCT02062697","created_at":"2021-01-18T09:30:05.355Z","updated_at":"2024-07-02T16:36:49.646Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.","source_id_and_acronym":"NCT02062697 - LUDOC","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2020-02-25"},{"id":"bbd1a478-a3ea-4485-aa56-e8b3f93758ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT01975701","created_at":"2021-01-18T08:59:44.203Z","updated_at":"2024-07-02T16:36:52.939Z","phase":"Phase 2","brief_title":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","source_id_and_acronym":"NCT01975701","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGFR2 • FGFR3 • FGFR1 • TACC3 • TACC1","pipe":" | ","alterations":" FGFR2 mutation • FGFR3-TACC3 fusion • FGFR2 fusion • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion • FGFR translocation","tags":["FGFR2 • FGFR3 • FGFR1 • TACC3 • TACC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR3-TACC3 fusion • FGFR2 fusion • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion • FGFR translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 12/09/2013","start_date":" 12/09/2013","primary_txt":" Primary completion: 10/03/2018","primary_completion_date":" 10/03/2018","study_txt":" Completion: 10/03/2018","study_completion_date":" 10/03/2018","last_update_posted":"2019-12-04"},{"id":"4e06d46a-253b-484d-a0a2-bca662c63ece","acronym":"","url":"https://clinicaltrials.gov/study/NCT01004224","created_at":"2021-01-17T17:13:53.960Z","updated_at":"2024-07-02T16:36:54.872Z","phase":"Phase 1","brief_title":"A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT01004224","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGFR2 • FGFR3","pipe":" | ","alterations":" FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification","tags":["FGFR2 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 12/11/2009","start_date":" 12/11/2009","primary_txt":" Primary completion: 10/08/2018","primary_completion_date":" 10/08/2018","study_txt":" Completion: 10/08/2018","study_completion_date":" 10/08/2018","last_update_posted":"2019-10-04"}]